Literature DB >> 15722654

Combination therapy in the management of hypertension: focus on angiotensin receptor blockers combined with diuretics.

Paolo Palatini1.   

Abstract

There is increasing evidence that combination therapy should be emphasized more than it is at present for the initial treatment of hypertensive patients. Recent guidelines acknowledge the value of combination therapy, although some treatment algorithms fail to echo this message. Observations from major clinical trials in the elderly, diabetics, stroke patients, and African Americans all indicate that combination therapy is necessary to control blood pressure in the majority of these patients. Several combination therapies such as an angiotensin II receptor blocker and a diuretic, an angiotensin-converting enzyme inhibitor with a diuretic, a beta blocker with a diuretic, or an angiotensin-converting enzyme inhibitor with a calcium antagonist have been shown to be effective in patients who do not respond to monotherapy. The current review focuses on the newest such combination; an angiotensin II receptor blocker and a diuretic may have an added advantage of being well tolerated. Recent studies have shown that angiotensin II receptor blockers, given alone or combined with a diuretic, may prevent some cardiovascular outcomes independent of their blood pressure-lowering efficacy.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15722654      PMCID: PMC8109366          DOI: 10.1111/j.1524-6175.2005.03793.x

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN: 1524-6175            Impact factor:   3.738


  35 in total

1.  Comparison of the AT1-receptor blocker, candesartan cilexetil, and the ACE inhibitor, lisinopril, in fixed combination with low dose hydrochlorothiazide in hypertensive patients.

Authors:  G T McInnes; K P O'Kane; H Istad; S Keinänen-Kiukaanniemi; H F Van Mierlo
Journal:  J Hum Hypertens       Date:  2000-04       Impact factor: 3.012

2.  Baseline Characteristics and Early Blood Pressure Control in the CONVINCE Trial.

Authors:  Henry R. Black; William J. Elliott; James D. Neaton; Gregory Grandits; Patricia Grambsch; Richard H. Grimm; Lennart Hansson; Yves Lacoucière; James Muller; Peter Sleight; Michael A. Weber; William B. White; Gordon Williams; Janet Wittes; Alberto Zanchetti; T. Daniel Fakouhi; Robert J. Anders
Journal:  Hypertension       Date:  2001-01       Impact factor: 10.190

3.  Effects of treatment on morbidity in hypertension. Results in patients with diastolic blood pressures averaging 115 through 129 mm Hg.

Authors: 
Journal:  JAMA       Date:  1967-12-11       Impact factor: 56.272

4.  A comparison of outcomes with angiotensin-converting--enzyme inhibitors and diuretics for hypertension in the elderly.

Authors:  Lindon M H Wing; Christopher M Reid; Philip Ryan; Lawrence J Beilin; Mark A Brown; Garry L R Jennings; Colin I Johnston; John J McNeil; Graham J Macdonald; John E Marley; Trefor O Morgan; Malcolm J West
Journal:  N Engl J Med       Date:  2003-02-13       Impact factor: 91.245

5.  Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack.

Authors: 
Journal:  Lancet       Date:  2001-09-29       Impact factor: 79.321

6.  A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial.

Authors:  Carl J Pepine; Eileen M Handberg; Rhonda M Cooper-DeHoff; Ronald G Marks; Peter Kowey; Franz H Messerli; Giuseppe Mancia; José L Cangiano; David Garcia-Barreto; Matyas Keltai; Serap Erdine; Heather A Bristol; H Robert Kolb; George L Bakris; Jerome D Cohen; William W Parmley
Journal:  JAMA       Date:  2003-12-03       Impact factor: 56.272

7.  Comparison of valsartan 160 mg with lisinopril 20 mg, given as monotherapy or in combination with a diuretic, for the treatment of hypertension: the Blood Pressure Reduction and Tolerability of Valsartan in Comparison with Lisinopril (PREVAIL) study.

Authors:  Ettore Malacco; Massimo Santonastaso; Natale A Varì; Anna Gargiulo; Vitaliano Spagnuolo; Federico Bertocchi; Paolo Palatini
Journal:  Clin Ther       Date:  2004-06       Impact factor: 3.393

8.  Efficacy and tolerability of the combination valsartan/hydrochlorothiazide compared with amlodipine in a mild-to-moderately hypertensive Brazilian population.

Authors:  Roberto J S Franco; Suely Goldflus; Mari McQuitty; Wille Oigman
Journal:  Blood Press Suppl       Date:  2003-12

9.  Efficacy and tolerability of losartan versus enalapril alone or in combination with hydrochlorothiazide in patients with essential hypertension.

Authors:  R Townsend; B Haggert; C Liss; J M Edelman
Journal:  Clin Ther       Date:  1995 Sep-Oct       Impact factor: 3.393

10.  A multicenter, randomized, double-blind, placebo-controlled, 8-week trial of the efficacy and tolerability of once-daily losartan 100 mg/hydrochlorothiazide 25 mg and losartan 50 mg/hydrochlorothiazide 12.5 mg in the treatment of moderate-to-severe essential hypertension.

Authors:  Alan H Gradman; William E Brady; Lisa P Gazdick; Paulette Lyle; Robert K Zeldin
Journal:  Clin Ther       Date:  2002-07       Impact factor: 3.393

View more
  4 in total

1.  The role of baseline blood pressure in guiding treatment choice: a secondary analysis of the use of valsartan/hydrochlorothiazide as initial therapy in hypertensive adults in a randomized, double-blind, placebo-controlled trial.

Authors:  James L Pool; Robert Glazer; Nora Crikelair; Drew Levy
Journal:  Clin Drug Investig       Date:  2009       Impact factor: 2.859

2.  Effectiveness of hydrochlorothiazide in combination with telmisartan and olmesartan in adults with moderate hypertension not controlled with monotherapy: a prospective, randomized, open-label, blinded end point (PROBE), parallel-arm study.

Authors:  Roberto Fogari; Annalisa Zoppi; Amedeo Mugellini; Paola Preti; Maurizio Destro; Andrea Rinaldi; Giuseppe Derosa
Journal:  Curr Ther Res Clin Exp       Date:  2008-02

Review 3.  Pharmacotherapy review: Angiotensin receptor antagonists.

Authors:  Domenic A Sica
Journal:  J Clin Hypertens (Greenwich)       Date:  2005-11       Impact factor: 3.738

4.  Efficacy and safety of a fixed combination of irbesartan/hydrochlorothiazide in Chinese patients with moderate to severe hypertension.

Authors:  Qi-Fang Huang; Chang-Sheng Sheng; Yan Li; Gen-Shan Ma; Qiu-Yan Dai; Ji-Guang Wang
Journal:  Drugs R D       Date:  2013-06
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.